News >

Sasine Highlights Strides With CAR T-Cell Therapy in Hematologic Cancers

Caroline Seymour
Published: Monday, Sep 16, 2019

Joshua P. Sasine, MD, PhD

Joshua P. Sasine, MD, PhD

The reach of CAR T-cell therapy is expanding, explained Joshua P. Sasine, MD, PhD, and with each additional analysis, the field of hematologic oncology is learning how to maximize the safety and efficacy of each emergent product.

“Now we have longer follow-up from the original clinical trials that continues to show the benefit patients are experiencing from the treatment,” said Sasine. “We are also learning more about how to use these products, including how to make them safer and [we’re getting better at being able to] predict who and when patients will derive the most benefit.”

Currently, there are 2 FDA-approved CD19-directed CAR T-cell therapies, axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah), which have both demonstrated encouraging clinical activity.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication